10-Q: Tenax Therapeutics Reports Q1 2025 Results, Bolstered by Recent Financing

Tenax Therapeutics reports increased operating expenses and net loss for Q1 2025, offset by a strong cash position following recent equity offerings.

Summary

• Tenax Therapeutics reported a net loss of $10.4 million for the three months ended March 31, 2025, compared to a net loss of $3.8 million for the same period in 2024.
• Research and development expenses increased to $5.7 million from $2.7 million year-over-year, primarily due to the ongoing Phase 3 LEVEL trial for oral levosimendan.
• General and administrative expenses rose to $5.7 million from $1.2 million year-over-year, driven by increased stock-based compensation and legal/professional fees.
• The company completed a private placement in March 2025, raising gross proceeds of $25.0 million.
• Cash and cash equivalents totaled $111.4 million as of March 31, 2025, which the company believes is sufficient to fund operations through 2027.
• The company is actively conducting the LEVEL clinical trial to evaluate levosimendan and plans to initiate a second Phase 3 study, LEVEL-2.
• Tenax intends to submit marketing authorization applications following completion of the two Phase 3 trials of levosimendan and, when appropriate, a single Phase 3 trial of imatinib.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has a strong cash position and is progressing its clinical trials, the increased net loss and operating expenses are concerning. The company's future success depends on the outcomes of its clinical trials and regulatory approvals.

Positives

• The company's cash position is strong at $111.4 million, providing a runway through 2027.
• The March 2025 private placement added $25.0 million in gross proceeds.
• The company is actively progressing its Phase 3 LEVEL trial for oral levosimendan.
• Tenax plans to initiate a second Phase 3 study, LEVEL-2, for levosimendan.
• The company intends to submit marketing authorization applications following successful Phase 3 trials.

Negatives

• The net loss increased significantly to $10.4 million in Q1 2025.
• Operating expenses, including research and development and general and administrative, have increased substantially.
• The company has an accumulated deficit of $325.3 million as of March 31, 2025.
• The company expects to continue to incur net losses for at least the next several years.

Risks

• The company's future capital requirements depend on numerous factors, including clinical trial outcomes and regulatory approvals.
• The company's ability to continue development beyond 2027 depends on obtaining license income, warrant exercises, or outside financing.
• There is no assurance that the company will obtain any license agreement or outside financing.
• The company's success depends on the successful development and commercialization of its product candidates.

Future Outlook

Tenax Therapeutics believes it has sufficient capital to fund operations through 2027 and intends to advance its Phase 3 oral levosimendan program, complete the ongoing LEVEL study, and initiate a second global Phase 3 study, LEVEL-2, with plans to submit marketing authorization applications following completion of the two Phase 3 trials of levosimendan and, when appropriate, a single Phase 3 trial of imatinib.

Management Comments

• We employ a clinician-driven drug development approach, led by key opinion leaders and advised by thought leaders who are pulmonary hypertension and heart failure experts and informed by their clinical insights to precisely target disease pathophysiology.
• We believe this derisked approach of using already-approved drugs that provide well-established safety profiles from millions of patients, combined with a development path led by preeminent cardiology and pulmonary hypertension experts, puts us in a strong position to deliver breakthrough cardiopulmonary therapies designed to improve patients function and quality of life.

Industry Context

Tenax Therapeutics is focused on developing therapies for cardiopulmonary diseases, particularly pulmonary hypertension, an area with significant unmet medical need. The company's approach of repurposing already-approved drugs aims to reduce development risk and accelerate the path to market.

Comparison to Industry Standards

• Tenax is pursuing a strategy of repurposing drugs, similar to companies like Biohaven Pharmaceuticals (now part of Pfizer) which successfully developed and commercialized rimegepant (Nurtec ODT) for migraine.
• The company's focus on pulmonary hypertension aligns with the efforts of companies like United Therapeutics and Acceleron Pharma (now part of Merck), which have developed and marketed therapies for PAH.
• The cash runway through 2027 provides Tenax with a competitive advantage, allowing it to focus on clinical development without immediate concerns about funding, similar to how larger pharmaceutical companies manage their long-term pipelines.

Stakeholder Impact

• Shareholders will be impacted by the increased net loss and potential dilution from future equity offerings.
• Employees will be affected by the company's ability to fund operations and continue development programs.
• Patients with pulmonary hypertension may benefit from the successful development and commercialization of levosimendan and imatinib.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Complete the ongoing Phase 3 LEVEL study.
• Initiate a second global Phase 3 study, LEVEL-2.
• Submit marketing authorization applications following completion of the two Phase 3 trials of levosimendan.
• Potentially develop imatinib for PAH.

Key Dates

Keywords

levosimendan, pulmonary hypertension, clinical trial, financing, research and development, Tenax Therapeutics, imatinib, operating expenses, net loss, private placement